Management of toxic epidermal necrolysis and related syndromes

Postgraduate Medical Journal

Volumn 84, Issue 988, 2008, Pages 60-65

  Mukasa, Y ^a   Craven, N ^a  

^a MACCLESFIELD DISTRICT GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; AMINOPENICILLIN; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; CD40 ANTIGEN; CD40 LIGAND; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; FAS LIGAND; IMIDAZOLE DERIVATIVE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE DERIVATIVE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

CALORIC INTAKE; CELLULAR IMMUNITY; CLINICAL FEATURE; CYTOKINE PRODUCTION; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; EPIDEMIOLOGICAL DATA; ERYTHEMA MULTIFORME; EYE INJURY; FLUID THERAPY; HERPES SIMPLEX; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; MACULOPAPULAR RASH; MORTALITY; PATHOGENESIS; PATIENT EDUCATION; PLASMAPHERESIS; POLYPHARMACY; PROGNOSIS; PROTEIN DIET; RECURRENT INFECTION; REVIEW; SKIN BIOPSY; SKIN INFLAMMATION; SKIN MANIFESTATION; SKIN NECROSIS; STEROID THERAPY; STEVENS JOHNSON SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PLASMAPHERESIS; PROGNOSIS; RENAL DIALYSIS; SEPSIS; STEROIDS;

EID: 41149083007     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2007.061465     Document Type: Review

References (42)

1. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 1993;129:92-6.
2. Assier H, Bastuji-Garin S, Revus J, et al. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. 1995;131:539-43.
3. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.
4. Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug aetiology in France, 1981-1985. Arch Dermatol 1990;126:103-4.
5. Rzany B, Mockenhaupt M, Stocker U, et al. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acguired immunodeficiency syndrome in Germany. Arch Dermatol 1993;129:1059.
6. Saiag P, Caumes E, Chosidow O, et al. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1992;26:567-74.
7. Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000;136:323-7.
8. Roujeau JC, Huynh TN, Bracq C, et al. Genetic susceptibility to toxic epidermal necrolysis. Ach Dermatol 1987;123:1171-3.
9. Wolkenstein P, Charue D, Laurent P, et al. Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulphonamides and anticonvulsants. Arch Dermatol 1995;131:544-51.
10. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical factors and prognostic factors in 87 patients. Ach Dermatol 1987;123:1160-5
11. Werhli P, Viard I, Bullani R, et al. Death receptors in cutaneous biology and disease. J Invest Dermatol 2000;115:141-8.
12. Rhodes LE, Hashim IA, McLaughlin PJ, et al. Blister fluid cytokines in cutaneous inflammatory bullous disorders, Acta Derm Venereol 1999;79:288-90.
13. Paquet P, Nikkeis A, Arresee JE, et al. Macrophages and tumour necrosis factors alpha in toxic epidermal necrolysis. Arch Dermatol 1994;130:605-8.
14. Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a mechanism of keratinocyte cell death in toxic epidermal necrolysis. Br J Dermatol 1996;134:710-14.
15. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human immunoglobulin. Science 1998;282:490-3.
16. Caproni M, Torchia D, Schincaglia E, et al. The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Br J Dermatol 2006;154:319-24.
17. Stur K, Karlhofer FM, Stingl G. Soluble Fas ligand: a discriminating factor between drug-induced skin eruptions and viral exanthemas. J Invest Dermatol 2007;127:802-7.
18. Abe R, Shimizu T, Shibaki A, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003;162:1515-20.
19. Murata J, Abe R. Soluble Fas ligand: is it a critical mediator of toxic epidermal necrolysis and Stevens-Johnson syndrome? J Invest Dermatol 2007;127:744-5.
20. Revuz R, Roujeau JC, Guillaume JC, et al. Treatment of toxic epidermal necrolysis. Arch Dermatol 1987;123:1156-8.
21. Roujeau JC, Chosidow O, Saiag P, et al. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990;23:1039-58.
22. Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 1997;23:1237-44.
23. Ramussen JC. Erythema multiforme in children. Response to treatment with systemic steroids. Br J Dermatol 1976;95:181-6.
24. Halebian PH, Corder VJ, Madden MR, et al. Improved burn centre survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986;205:503-12.
25. Guibal F, Bastuji-Garin S, Chosidow O, et al. Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol 1995;131:669-72.
26. Martinez AE, Atherton DJ. High-dose systemic corticosteroids can arrest recurrences of severe mucocutaneous erythema multiforme. Paediatr Dermatol 2000;17:87-90.
27. Stables GI, Lever RS. Toxic epidermal necrolysis and systemic corticosteroids. Br J Dermatol 1993;128:357.
28. Arevalo JM, Lorente JA, Gonzales-Herrada C, et al. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000;48:473-8.
29. Friedman Ps, et al. Investigation of mechanism in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994;130:598.
30. Heng MCY, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis. J Am Acad Dermatol 1991;25:778-86.
31. Redondo P, de Felipe I, de la Pena A, et al. Drug- induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcyteine. Br J Dermatol 1997;136:645-6.
32. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586-9.
33. Viard I, Werhli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-3.
34. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139:26-32.
35. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003;139:33-6.
36. Kamanbroo D, Schmitz-Landgraf W, Czarnetski BM. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 1985;121:1548-9.
37. Egan CA, grant WJ, Morris SE, et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999;40:458-9.
38. Furubacke A, Berlin G, Anderson C, et al. Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis. Intensive Care Med 1999;25:1307-10.
39. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85.
40. Hughes AP, Callen JP. Drug-induced linear IgA bullous dermatosis mimicking toxic epidermal necrolysis. Dermatology 2001;202:138.
41. Bastuji-Garin S, Fouchard N, Bertocci M, et al. SCORTEN: a severity of illness score for toxic epidermal necrolysis. J Invest Dermatol 200;115:149-53.
42. Fischer PR, Shigeoka AO. Familial occurrence of Stevens-Johnson syndrome. Am J Dis Child 1983;137:914-16.